129 related articles for article (PubMed ID: 25241128)
1. SAHA-based novel HDAC inhibitor design by core hopping method.
Zang LL; Wang XJ; Li XB; Wang SQ; Xu WR; Xie XB; Cheng XC; Ma H; Wang RL
J Mol Graph Model; 2014 Nov; 54():10-8. PubMed ID: 25241128
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI
ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563
[TBL] [Abstract][Full Text] [Related]
4. A cyclodextrin-capped histone deacetylase inhibitor.
Amin J; Puglisi A; Clarke J; Milton J; Wang M; Paranal RM; Bradner JE; Spencer J
Bioorg Med Chem Lett; 2013 Jun; 23(11):3346-8. PubMed ID: 23591111
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Han L; Wang L; Hou X; Fu H; Song W; Tang W; Fang H
Bioorg Med Chem; 2014 Mar; 22(5):1529-38. PubMed ID: 24525003
[TBL] [Abstract][Full Text] [Related]
6. SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders.
Fischer JJ; Michaelis S; Schrey AK; Diehl A; Graebner OY; Ungewiss J; Horzowski S; Glinski M; Kroll F; Dreger M; Koester H
Proteomics; 2011 Oct; 11(20):4096-104. PubMed ID: 21898820
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
Huang WJ; Chen CC; Chao SW; Yu CC; Yang CY; Guh JH; Lin YC; Kuo CI; Yang P; Chang CI
Eur J Med Chem; 2011 Sep; 46(9):4042-9. PubMed ID: 21712146
[TBL] [Abstract][Full Text] [Related]
8. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
Guan P; Wang L; Hou X; Wan Y; Xu W; Tang W; Fang H
Bioorg Med Chem; 2014 Nov; 22(21):5766-75. PubMed ID: 25311567
[TBL] [Abstract][Full Text] [Related]
9. Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Nam NH; Huong TL; Dung do TM; Dung PT; Oanh DT; Quyen D; Thao le T; Park SH; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB
Eur J Med Chem; 2013; 70():477-86. PubMed ID: 24185378
[TBL] [Abstract][Full Text] [Related]
10. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
[TBL] [Abstract][Full Text] [Related]
11. Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
Suzuki T; Kouketsu A; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N
Bioorg Med Chem Lett; 2004 Jun; 14(12):3313-7. PubMed ID: 15149697
[TBL] [Abstract][Full Text] [Related]
12. Thiol versus hydroxamate as zinc binding group in HDAC inhibition: An ab initio QM/MM molecular dynamics study.
Gong W; Wu R; Zhang Y
J Comput Chem; 2015 Nov; 36(30):2228-35. PubMed ID: 26452222
[TBL] [Abstract][Full Text] [Related]
13. Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
Taddei M; Cini E; Giannotti L; Giannini G; Battistuzzi G; Vignola D; Vesci L; Cabri W
Bioorg Med Chem Lett; 2014 Jan; 24(1):61-4. PubMed ID: 24345446
[TBL] [Abstract][Full Text] [Related]
14. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
[TBL] [Abstract][Full Text] [Related]
16. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Uba AI; Yelekçi K
J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
[TBL] [Abstract][Full Text] [Related]
17. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Oanh DT; Hai HV; Park SH; Kim HJ; Han BW; Kim HS; Hong JT; Han SB; Hue VT; Nam NH
Bioorg Med Chem Lett; 2011 Dec; 21(24):7509-12. PubMed ID: 22036991
[TBL] [Abstract][Full Text] [Related]
18. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
Finnin MS; Donigian JR; Cohen A; Richon VM; Rifkind RA; Marks PA; Breslow R; Pavletich NP
Nature; 1999 Sep; 401(6749):188-93. PubMed ID: 10490031
[TBL] [Abstract][Full Text] [Related]
19. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
Liao V; Liu T; Codd R
Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
[TBL] [Abstract][Full Text] [Related]
20. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures.
Mai A; Massa S; Ragno R; Cerbara I; Jesacher F; Loidl P; Brosch G
J Med Chem; 2003 Feb; 46(4):512-24. PubMed ID: 12570373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
